Robert Charles Benedetti, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Clara Maass Dr, Belleville, NJ 07109 Phone: 973-450-2480 Fax: 973-844-4976 |
Dr. Essel Marie B De Leon, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr, Pathology Department, Belleville, NJ 07109 Phone: 973-450-2480 |
Dr. John Kopf Donahue, MD, MPH Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr, Belleville, NJ 07109 Phone: 973-450-2245 Fax: 973-844-4976 |
News Archive
CMS has not conducted audits to ensure that Medicare prescription drug plans have implemented programs to prevent fraud as required by law, a lack of oversight that "risks significant misuse of funds in this $39 billion program," according to a Government Accountability Office report scheduled for release on Monday, the AP/Orlando Sentinel reports. For the report, GAO examined five unnamed plans to determine whether they met requirements to participate in the Medicare prescription benefit.
Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life sciences process applications, announced the production release of its single-use sensor product family: TruFluor sensors for dissolved oxygen or pH and process temperature, and TruTorr headspace pressure sensors.
Duke Researchers have pinpointed a new therapeutic target for macular degeneration, an eye disease that affects over 10 million Americans and is the leading cause of blindness in adults over 60.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago